ATYR: aTyr Pharma Inc Company Value to Net Income
The current price chart for aTyr Pharma, Inc. (ATYR) demonstrates the -0.30 metric, while the company is recognized as an innovator in the therapy of immune pathologies and is highly valued by pulmonologists for its fight against fibrosis. The business relies on a tRNA synthetase platform, seeking to attract partners to combat rare inflammatory conditions. Currently, the firm's potential is being realized through preparations to publish key results from the final stage of trials for its new drug.
%20P%2FE%20Multiple&width=1200&height=400&colorIndex=0&v=mwg3sw3k.w4s-7di3ke8&start=20220704&end=20261114&filename=GURU_Markets_-_ATYR_-_aTyr-Pharma-Inc._-_PE-Multiple "ATYR: aTyr Pharma, Inc. Business Payback Period 06/06/2024 - 11/14/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for aTyr (ATYR)
- price and consensus price forecast:
- market capitalization information:
- balance sheet net asset value indicators:
- debt and solvency information:
- earnings and market multiples details:
ATYR - Net Income|Future Net Profit aTyr Pharma, Inc.|ATYR - Price to Earnings Ratio|Projected Price to Earnings Ratio aTyr Pharma Inc|ATYR - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation aTyr Pharma, Inc.|ATYR - Operating profit before deduction of amortization|Earnings per share for the trailing year aTyr Pharma|ATYR - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months atyrpharma.com|ATYR - Earnings growth in current year|Expected earnings per share trend next year aTyr Pharma, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:atyrpharma.com ATYR
The P/E ratio measures a business's market value relative to its net income, allowing investors to determine the extent of an asset's overvaluation and assess a fair capitalization level. By analyzing the price-to-earnings dynamics of aTyr Pharma, Inc. (ATYR), an investor will observe biotech specifics: a minimal environmental footprint and a focus on laboratory protocols render earnings volatile, turning this indicator into a filter against critical price overheating.
Key competitors
P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN (Precigen, Inc.) - Price to Earnings Ratio|PHAR: Market Price to Net Income Ratio|Price to Earnings Ratio NKTR|Market Cap to Earnings Upstream Bio, Inc. UPB|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Company Value to Net Income|Gossamer Bio, Inc. - Price to Earnings Ratio|Company Value to Net Income KALV|SEPN - Price to Earnings Ratio|Market Cap to Net Income PVLA|SVRA: P/E Multiple|Rigel Corp - Company Value to Net Income|ANAB (AnaptysBio, Inc.) - P/E Multiple|P/E Multiple astriatx.com|Price to Earnings Ratio enGene (ENGN)|RAPT (RAPT Therapeutics Inc.) - Company Value to Net Income|Price to Earnings Ratio Aerovate Therapeutics JBIO|ACRS - Price to Earnings Ratio|Kyverna Therapeutics - P/E Multiple|TLSA - P/E Multiple|CABA (Cabaletta Bio) - Price to Earnings Ratio|Ventyx Biosciences Inc. - Company Value to Net Income|THTX (Theratechnologies Inc) - P/E Multiple|Avalo Therapeutics Inc (AVTX) - Business Payback Period|Price to Earnings Ratio Eledon Pharmaceuticals (ELDN)|agenusbio.com - Price to Earnings Multiple|P/E Multiple CLYM (Climb Bio)|ZURA - Price to Earnings Ratio|ADAG: Price to Earnings Ratio|Business Payback Period ImageneBio Inc IMA|STTK: P/E Multiple|Equillium (EQ) - P/E Multiple|Price to Earnings Ratio CNTB|IMUX (Immunic Inc) - Market Price to Net Income Ratio|Price to Earnings Ratio ATRA (Atara Biotherapeutics)|IFRX - Market Cap to Earnings|Price to Earnings Ratio X4 Pharmaceuticals XFOR|Company Value to Net Income ACET|CELU - Price to Earnings Ratio|Market Cap to Net Income INMB|BRNS: P/E Multiple|Kezar Life Sciences Inc - Company Value to Net Income|SABS (SAB Biotherapeutics) - P/E Multiple|P/E Multiple akaritx.com|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|QTTB (q32bio.com) - Company Value to Net Income|Price to Earnings Ratio GeoVax Labs Inc GOVX|EDSA - Price to Earnings Ratio|iBio, Inc. - P/E Multiple|CARM - P/E Multiple|XTLB (XTL Biopharmaceuticals Ltd.) - Price to Earnings Ratio|Bolt Biotherapeutics, Inc. - Company Value to Net Income|HCWB (HCW Biologics, Inc.) - P/E Multiple|Aptevo (APVO) - Business Payback Period|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|Price to Earnings Ratio aditxt.com ADTX|Price to Earnings Ratio GRI Bio GRI|XRTX - Price to Earnings Ratio|HIND: Price to Earnings Ratio|REVB - P/E Multiple|Indaptus Therapeutics (INDP) - Price to Earnings Ratio|Price to Earnings Multiple SCNI|CALI (CalciMedica Inc) - P/E Multiple|Market Cap to Earnings Affimed Therapeutics AFMD|P/E Multiple ALLK|P/E Multiple hookipapharma.com (HOOK)|IGM Biosciences - Price to Earnings Ratio|Market Price to Net Income Ratio ITOS (iteostherapeutics.com)|OCEA: Price to Earnings Ratio|Market Cap to Earnings TC BioPharm (Holdings) Plc|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio
